ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2834

Healthcare Cost Drivers in Rheumatoid Arthritis

Nina Mars1, Anne M Kerola2,3, Markku J Kauppi4,5, Matti Pirinen1, Outi Elonheimo6 and Tuulikki Sokka-Isler7, 1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 2Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 3University of Helsinki, Helsinki, Finland, 4School of Medicine, University of Tampere, Tampere, Finland, 5Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, 6FCG Finnish Consulting Group Ltd., Helsinki, Finland, 7Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: administrative databases, Disease Activity, Health Care, Health care cost and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Health Services Research I: Cost Drivers in Rheumatic Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare resource utilization, but knowledge about factors determining healthcare costs is limited. The aim was to identify healthcare cost drivers in RA.

Methods: RA patients attending Jyvaskyla Central Hospital (JCH) rheumatology unit, Finland, are as of 2007 prospectively enrolled in a structured digital database. We combined this clinical data with well-recorded administrative data on all primary and specialty healthcare in visits in Jyvaskyla area from fiscal year 2014. We excluded 46 outliers, defined as patients with annual costs exceeding the geometric mean by two standard deviations. For each patient, we considered the median of time dependent clinical variables: disease activity score (DAS28-3), health assessment questionnaire index (HAQ index, 0-3), and pain on visual analogue scale (VAS, 0-100). In patients with non-zero costs, factors affecting annual costs (€) were assessed with an age-stratified multivariate generalized linear model using Gamma distribution and a log link function. Variables were selected by statistical significance in univariate analyses. All multivariate analyses were adjusted for age in years or disease duration, and sex. To increase interpretability, we calculated marginal effects at the means of the independent variables. This displays how the annual costs are affected when a variable increases by one unit, while the other variables remain unchanged.

 

Results: Three age groups were analysed separately: 18-50 (n = 179), 51-70 (n = 477) and 71-100 (n = 300), with mean per-patient annual healthcare costs being 2,942€, 2,914€ and 4,026€, respectively. The main factor associated with healthcare costs across all age groups was disease activity: an increase in the long-term median level of DAS28(3) of an individual yielded up to a 848€ to 1,063€ increase in annual costs (Table 1). In terms of other clinical measures, strong evidence of an association was present for pain in those 18-50 (31€ per one point increase in VAS, p = 0.002) and for number of comorbidities in those 51-70 (317€ per comorbidity, p < 0.001).

 

Conclusion: A main cost driver in all age groups was disease activity.

Table 1. Multivariate generalized linear model for annual costs, stratified by age. The marginal effects were calculated at the means of the independent variables. For continuous variables, the marginal effect displays how the annual costs are affected when the variable increases by one unit, while the other variables remain unchanged. For dichotomous variables, the change represents comparison to the reference group.

Screen%20Shot%202017-06-18%20at%2019.04.10.png


Disclosure: N. Mars, None; A. M. Kerola, None; M. J. Kauppi, None; M. Pirinen, None; O. Elonheimo, Finnish Consulting Group Ltd, 3; T. Sokka-Isler, None.

To cite this abstract in AMA style:

Mars N, Kerola AM, Kauppi MJ, Pirinen M, Elonheimo O, Sokka-Isler T. Healthcare Cost Drivers in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/healthcare-cost-drivers-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/healthcare-cost-drivers-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology